Inattention News and Research

RSS

Socioeconomic factors predict ADHD-medication in Swedish schoolchildren

A major study of more than a million children has found strong links between receiving medication for attention deficit hyperactivity disorder (ADHD) and limited maternal education, single parent families and welfare benefits, according to the June issue of Acta Paediatrica.

1 Jun 2010

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced the results of a study evaluating the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder in adolescents aged 13 to 17 years.

26 May 2010

State of California adds Distracted Driving as new area for concentrated effort to SHSP

Driver distractions have joined alcohol and speeding as leading factors in fatal and serious injury crashes. The National Safety Council estimates that up to 25 percent of all crashes in 2008 involved talking on cell phones or texting. To combat this growing threat on our roadways, the State of California has added Distracted Driving as the first new area for concentrated effort to the Strategic Highway Safety Plan.

23 Apr 2010

NPR's Car Talk guys team up with University of Utah to launch Driver Distraction Center

NPR's Car Talk guys, Tom and Ray Magliozzi, may be a couple of motor mouths, but they always put a lid on using cell phones behind the wheel. The perennial jokesters confirm their serious commitment to addressing the issue of devices that take a driver's focus off the road by teaming with the University of Utah to launch the Driver Distraction Center at their web site: cartalk.com/distraction.

23 Mar 2010

Texting-on-the-go can cause fatal accidents

Siobhan Wicks was texting her roommate while walking down the stairs in her Aurora home when suddenly her world turned topsy turvy.

9 Feb 2010

Shire announces the Canadian availability of VYVANSE prodrug therapy for ADHD treatment

Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Today, Shire plc, the global specialty biopharmaceutical company, announced the Canadian availability of VYVANSE (lisdexamfetamine dimesylate capsule), the first and only prodrug therapy approved for ADHD treatment in Canada.

2 Feb 2010

New research suggests lead may trigger attention-deficit/hyperactivity disorder

ADHD, or attention-deficit/hyperactivity disorder, is among the costliest of behavioral disorders. Its combination of inattention, impulsivity and hyperactivity leads to accidental injuries, school failure, substance abuse, antisocial behavior and more. Yet despite nearly a century of study, the disorder's roots remain mysterious.

29 Jan 2010

System to help identify patients at high risk of developing delirium

A specialist in caring for elderly patients, Turner-Hubbard is a geriatric nurse practitioner trained to quickly spot the sudden changes in mental status that signal the onset of the sudden, severe confusion known as delirium. She knows the hospital “triggers” that can bring on fluctuations in behavior: blood loss during surgery, anesthesia, pain medications and anti-anxiety drugs, infections, dehydration, IV lines and catheters, as well as being immobilized for an extended period of time.

19 Nov 2009

Poor mental health in children and teenagers impacts on the length of time they will stay in school: Study

"Our study shows that poor mental health in children and teenagers has a large impact on the length of time they will stay in school," says Dr. Lehrer. He notes a large number of school-based programs have recently been introduced to prevent childhood obesity through lifestyle changes, but suggests the net should be cast more widely. "It's important for policymakers to target health conditions that are not the easiest to identify - like inattention - but may have larger impacts on one's future."

13 Nov 2009

Online patient support program for ADHD patients taking Vyvanse Capsules CII medication

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the re-launch of FOCUS (http://www.vyvanseFOCUS.com), a free, online patient support program for adults taking once-daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded personalized patient support program providing tips and tools for adults diagnosed with ADHD taking a prescription medication.

11 Nov 2009

Cost of ADHD clinical trials can be reduced by implementing Quotient ADHD System

BioBehavioral Diagnostics Company announced today that its poster was presented Friday, October 30, 2009 after it was accepted via a rigorous peer-review process and included as a New Research Poster presentation at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Honolulu, HI, October 27-November 1, 2009.

4 Nov 2009

Pilot study examines the concordance of Quotient ADHD Test

BioBehavioral Diagnostics Company announced today that their poster has been accepted through a rigorous peer-review process for inclusion as a New Research Poster presentation at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Honolulu, HI, October 27-November 1, 2009.

22 Oct 2009

Orient Pharma granted commercialization rights for a drug candidate by DURECT

DURECT Corporation today announced that it has signed a development and license agreement with Orient Pharma Co., Ltd., a diversified multinational pharmaceutical, healthcare and consumer products company with headquarters in Taiwan, under which DURECT has granted to Orient Pharma development and commercialization rights in selected Asian and South Pacific countries to a drug candidate based on DURECT's ORADUR(R) Technology and one specified active pharmaceutical ingredient for the treatment of attention deficit hyperactivity disorder (ADHD).

19 Aug 2009

Shire starts two adult ADHD outreach programs

Shire plc today announced two initiatives reinforcing their commitment to the care of adults with Attention-Deficit/Hyperactivity Disorder (ADHD), a psychiatric behavioral disorder that affects an estimated 10 million adults across the country.

18 Aug 2009

Piecing together the HIV prevention puzzle

"It's an exciting time in HIV prevention research. We will see results from a number of critically important HIV prevention research trials this year, as well as see the start of new trials around the world that will yield important answers in the years to come," said Mitchell Warren, AVAC executive director, at the release of AVAC's 13th annual report of the field.

18 May 2009

Good sleep patterns among children important in preventing behavioral symptoms

A recent Finnish study suggests that children's short sleep duration even without sleeping difficulties increases the risk for behavioral symptoms of ADHD.

27 Apr 2009

Thinning of right hemisphere in brain a marker for familial form of depression

Findings from one of the largest-ever imaging studies of depression indicate that a structural difference in the brain - a thinning of the right hemisphere - appears to be linked to a higher risk for depression, according to new research at Columbia University Medical Center and the New York State Psychiatric Institute.

23 Mar 2009

Shire withdraws European application for Daytrana (Methylphenidate Transdermal System)

Shire plc has announced that it has decided to withdraw the European Marketing Authorization Application (MAA) for Daytrana (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

16 Mar 2009

Shire to enter European ADHD market with acquisition of EQUASYM IR and XL

Shire plc has announced that it has signed an agreement with UCB to acquire the worldwide rights to EQUASYM IR and XL (methylphenidate hydrochloride) (excluding the USA, Canada and Barbados) used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

22 Feb 2009

Latest genetic research on ADHD

A special issue of American Journal of Medical Genetics (AJMG): Part B: Neuropsychiatric Genetics presents a comprehensive overview of the latest progress in genetic research of Attention Deficit/Hyperactivity Disorder (ADHD).

7 Jan 2009